# NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

* Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital.
* Combined with a prior strategic investment, for which a financing term sheet has also been signed, the total financing investment, assuming both are closed, represents an expected $10.3 million for HOPE acquisition funding, supporting initial acquisitions of Dura Medical, Kadima, and NeuroSpa clinics.
* The expanding HOPE clinic network will deliver neuroplastic therapies for depression and PTSD, including ketamine and TMS.
* NRx continues regulatory progress for NRX-100 (IV ketamine) and NRX-101 (oral bipolar depression therapy).
* The FDA waived NRx’s $4.3 million drug application fee, and patents could protect NRX-100 through 2045.

 NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, is advancing its twin strategy of expanding a nationwide mental health clinic network while progressing toward FDA approval of its NMDA-based therapies for suicidal depression and bipolar disorder.

 The company’s wholly owned subsidiary, HOPE Therapeutics, Inc., a medical and technology-driven company, has signed a term sheet for $7.8 million in debt financing with Universal Capital, LLC (https://ibn.fm/tZzIa). The funds will support HOPE’s clinic acquisition strategy, starting with the…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

 About PsychedelicNewsWire

 PsychedelicNewsWire (“PNW”) is a specialized communications platform with a focus on all aspects of psychedelics and the latest developments and advances in the psychedelics sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, PNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, PNW brings its clients unparalleled recognition and brand awareness. PNW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from PsychedelicNewsWire, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.PsychedelicNewsWire.com

 Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

 PsychedelicNewsWireSan Francisco, CAwww.PsychedelicNewsWire.com415.949.5050 OfficeEditor@PsychedelicNewsWire.com

 PsychedelicNewsWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/pnw/nrx-pharmaceuticals-inc-nasdaq-nrxp-announces-10-3-million-financing-to-expand-hope-clinic-network-advances-fda-drug-approval/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/nrx-pharmaceuticals-secures-7-8m-financing-for-hope-clinic-network-expansion/8b07f6bb1f19f3283e87b15829c8683d) 

 



[Reddit Post](https://www.reddit.com/r/PsychedelicsNews/comments/1kxjx5b/nrx_pharmaceuticals_secures_78m_financing_for/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/255/28/pitapicoZpNg.webp)